Why the study?
Do NSAIDs increase cardiovascular risk in clinical practice?
Do NSAIDs increase cardiovascular risk in clinical practice?
This review highlights the cardiovascular side effects associated with NSAID use, particularly COX-2 inhibitors, in clinical practice.
Answers are grounded in this paper and cite their sources.
Supports caution with NSAIDs, especially COX-2 inhibitors, in CV patients; leaves open precise contemporary risk quantification.
NSAIDs are the most largely used class of drugs in the world, due to their large use in many diseases, in particular for the systemic inflammatory diseases. Nevertheless, today NSAIDs are less used for some of these diseases, due to several side-effects correlated to these drugs. The antiinflammatory mechanism of NSAIDs consist in the inibhition of two forms of cyclooxygenase, namely COX-1 (its block contributes to an antiplatelet effect) and COX-2 (its block has a greater antiinflammatory, antipyretic and analgesic effect). The COX-2 inhibition might reduce the risk of gastrointestinal toxicity, but several studies have shown the cardiovascular side effects of this inhibition. Mechanisms of the cardiovascular side effects are controversial yet, so the aim of this document is to review side-effects profile of NSAIDs and, specifically, to investigate cardiovascular consequences of NSAIDs use in clinical practice.
No takes yet. Share an insight, caveat, or question.
Marsico et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: